Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Open-Label Extension and Safety Study of Talazoparib
Open-Label Extension and Safety Study of Talazoparib

NCT02921919

CompletedPhase 2

Sponsor: Pfizer

Conditions: Cancer

Interventions: Talazoparib

Countries: United States, Canada, France, Germany, Hungary, Moldova, Poland, Russia

This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
* Female patients of childbearing potential must have a negative pregnancy test before the first dose of talazoparib and must agree to use a highly effective birth control method from the time of the first dose of talazoparib through 45 days after the last dose.
* Male patients must use a condom when having sex with a pregnant woman or with a woman of childbearing potential from the time of the first dose of talazoparib through 105 days after the last dose. Contraception should be considered for a nonpregnant female partner of childbearing potential.
* Female patients may not be breastfeeding at the first dose of talazoparib and must not breastfeed during study participation through 45 days after the last dose of talazoparib.

Exclusion Criteria:

* Permanently discontinued from any Medivation sponsored study with talazoparib alone or in combination with another agent.
* Received an antineoplastic therapy or investigational agent after treatment with talazoparib in the originating protocol.
* Has a clinically significant cardiovascular, dermatologic, endocrine, gastrointestinal, hematologic, infectious, metabolic, neurologic, psychologic, or pulmonary disorder or any other condition, including excessive alcohol or drug abuse, or secondary malignancy, that may interfere with study participation in the opinion of the investigator.
* Diagnosis of myelodysplastic syndrome (MDS).
Locations (38)
  • Alhambra, California, United States
  • Bakersfield, California, United States
  • Burbank, California, United States
  • Fullerton, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • Los Angeles, California, United States
  • Pasadena, California, United States
  • Porter Ranch, California, United States
  • Santa Monica, California, United States
  • Torrance, California, United States
  • Valencia, California, United States
  • Orlando, Florida, United States
  • Pembroke Pines, Florida, United States
  • Bloomington, Indiana, United States
  • Fort Wayne, Indiana, United States
  • Fort Wayne, Indiana, United States
  • Indianapolis, Indiana, United States
  • Indianapolis, Indiana, United States
  • Indianapolis, Indiana, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • New Brunswick, New Jersey, United States
  • Houston, Texas, United States
  • Edmonton, Alberta, Canada
  • Hamilton, Ontario, Canada
  • Montreal, Quebec, Canada
  • Marseille, France
  • + 8 more on CT.gov